Taken together, parameters (including those in the current study) based on serum and PD effluent biochemistry, along with additional available data on bone mineral health (such as DEXA scan), may be analysed using multivariate regression to possibly pave the way for the development of a validated risk stratification tool centred on severity of CKD-MDB in PD patients. The gene discussed is ABR; the disease is chronic kidney disease.